Latest / Markets & Money News Today | 2 Min News | THE DAILY NOW!
Syndax Pharma Stock Falls After Trial Fail | Markets & Money News
Syndax Pharmaceuticals' stock plummeted 15% after its axatilimab drug failed to meet critical goals in a Phase two trial for idiopathic pulmonary fibrosis, specifically regarding forced vital capacity. Despite this setback, the drug demonstrated a good safety profile, similar to placebo, with no serious safety concerns. The trial's failure won't affect other ongoing studies related to axatilimab, which has FDA approval for treating chronic graft-versus-host disease. Syndax remains focused on
www.TheDailyNewsNow.com
This is an automated, high-level news summary based on public reporting and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.